Logo SEFAC
Farm Comunitarios. 2021 Oct 06;13(4):28-42. doi: 10.33620/FC.2173-9218.(2021/Vol13).004.05

Invasive meningococcal disease burden and prophylaxis: update on serogroup B vaccination

Cáceres R1, Guillén J2, González-Inchausti C3, Gómez Sobrino M3
1. Desarrollo de Proyectos Profesionales y Relaciones Institucionales, Colegio Oficial de Farmacéuticos de Sevilla. 2. Farmacéutico, Santa Perpètua de Mogoda. 3. GSK, Departamento Médico, Madrid.
Cáceres R, Guillén J, González-Inchausti C, Gómez M. Invasive meningococcal disease burden and prophylaxis: update on serogroup B vaccination. Farm Comunitarios. 2021 Oct 06;13(4):28-42. doi: 10.33620/FC.2173-9218.(2021/Vol13).004.05
Abstract : 

Invasive meningococcal disease (IMD) is a serious bacterial infection commonly presenting as meningitis or sepsis. Transmitted through the mouth and nose secretions, it has rapidly evolving symptoms that can cause death in 24-48 hours if untreated and may also have devastating consequences, such as loss of limbs, seizures, stroke, as well as impairment of vision, speech, and hearing. Serogroup (Men) B is the pathogen responsible for most of cases of IMD in Europe, America, and Australia. 

The World Health Organization considers that vaccination is the most effective approach to defeat meningococcal meningitis. For now, there is no single vaccine that protects against all serogroups causing IMD. Conjugate polysaccharide vaccines against MenACWY have been available for years, and only recently two MenB vaccines have been developed. MenACWY vaccination for adolescents aged 12 years is included in the Spanish National Immunization Program and the Spanish Association of Paediatrics suggests the systematic inclusion of the MenB vaccine as well for infants, as it is the most prevalent serogroup in Spain. Pharmacists play an essential role as healthcare agents, advising and dispensing every day to patients who visit the pharmacy. This review provides information that will help pharmacists to answer questions relevant to IMD and prophylaxis with the available vaccines, so that they can explain to parents the importance of booster doses and vaccination schedule completion.

 

Keywords : 
Meningococcal infections, Neisseria meningitidis, community pharmacy, pandemics, prevention and control, serogroup B, Spain, vaccination coverage, vaccines

Editor: © SEFAC. Sociedad Española de Farmacia Clínica, Familiar y Comunitaria. 
Copyright© SEFAC. Sociedad Española de Farmacia Clínica, Familiar y Comunitaria. This article is available from url https://www.farmaceuticoscomunitarios.org/. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

Share

-

Related contents

Published by

Manual for authors

Journal Information